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Abstract
Background: The Actinic Keratosis Quality of Life Question-
naire (AKQoL) is a disease-specific instrument to measure 
the impact of actinic keratosis (AK) on patients’ lives. Objec-
tive: To validate and test the psychometric properties of the 
AKQoL translated into the Dutch language (AKQoL-NL). 
Methods: All new patients ≥50 years of age with untreated 
AK in a university medical center and a general hospital 
between August 2014 and August 2015 were eligible. The 
AKQoL was obtained and repeated after 2 weeks. The feasi-
bility was tested by missing responses and response distri-
bution. The internal consistency reliability of each domain 
was investigated with the Cronbach alpha, and test-retest 
reliability and validity with the Spearman correlation coeffi-
cient. AKQoL scores were compared to the Skindex-17 for 
convergent validity and to the Groningen Frailty Indicator 
scores for divergent validity. Results: A total of 153 of 190 
eligible patients consented to participate. Feasibility analy-
sis showed that none of the items missed ≥10% of responses 
but 5 of the 9 items showed floor effect. The AKQoL sub-
scales showed a moderate internal consistency (Cronbach 
α = 0.235–0.468) and an excellent test-retest reliability (inter-
class correlation coefficient = 0.997–1). The AKQoL correlat-
ed poorly with the symptom component and moderately 
with the psychosocial component of the Skindex-17 (ρ = 
–0.015 to 0.346 and 0.324 to 0.501, respectively), which is less 
than expected. The AKQoL scored poorly in both of the Gron-
ingen Frailty Indicator (GFI) components (ρ = –0.97 to 0.12 
and 0.185 to 0.276, respectively), as expected. Conclusion: 
The AKQoL-NL is a feasible, moderately valid, and moder-
ately reliable health-related quality of life questionnaire.
© 2018 The Author(s)
Published by S. Karger AG, Basel
Introduction
Actinic keratosis (AK) is an epidermal manifestation 
of abnormal keratinocyte proliferation caused by expo-
sure to ultraviolet radiation. With an estimated preva-
lence of between 1.4 and 25% of the population [1–5], it 
is the most common premalignant condition in the Cau-
casian population.
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AKs usually are present as scaly, red lesions which may 
adhere to clothing, itch, or bleed and can therefore cause 
an uncomfortable physical experience. They are mostly 
located on skin areas chronically exposed to ultraviolet 
radiation, such as the face, scalp and dorsal hands, there-
by also causing cosmetic discomfort to the patient. Due 
to its premalignant nature the fear of developing skin can-
cer often arises, which could lead to anxiety and stress. 
Therefore, patients with AK may have health-related 
quality of life (HRQoL) impairment.
To determine the influence of dermatological diseases 
on this HRQoL, there are several instruments available [6, 
7]. These are generic questionnaires and are used for a 
variety of diseases in dermatology, which makes it pos-
sible to compare the burden of different conditions. As 
they are not disease-specific they might miss important 
aspects that have a great impact on the quality of life of 
specific patient groups. Therefore, the AKQoL was devel-
oped in 2012. 
It was the first disease-specific questionnaire for AK, 
which was demonstrated to be valid and to have an excel-
lent internal consistency, a high reproducibility, and a 
high responsiveness. It appears to be a valuable instru-
ment for assessing improvement in patients’ HRQoL in 
both clinical practice and trials [8].
Although the AKQoL has been frequently used, docu-
menting and testing its psychometric properties has been 
limited to the Spanish [9, 10] and Danish populations 
(original study [8]). Therefore, the objective of this study 
is to test the psychometric properties of the Dutch version 
of the AKQoL (AKQoL-NL) in a heterogeneous group of 
Dutch patients diagnosed with AK.
Materials and Methods
For further details, see the online supplementary material (see 
www.karger.com/doi/10.1159/000489118 for all online suppl. ma-
terial) [7, 11–18] (Fig. 1).
Results
Study Population
Of the 198 AK patients who were screened for inclu-
sion, 190 were eligible, of whom 153 consented to par-
ticipate (81%). The other 37 declined due to lack of time 
or interest. The mean age of the participants was 75 years, 
almost 60% were men, and the most common AK local-
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Fig. 1. Flowchart of Materials and Methods. AK, actinic keratosis; 
GFI, Groningen Frailty Indicator; T2, 2 weeks after the initial ques-
tionnaire.
Table 1. Patient characteristics
Male 90 (59)
Median age (IQR), years 74 (68–81)
Number of AKs 
1–3 52 (34)
4–9 61 (40)
≥10 40 (26)
Localization of AK
Face (including ears) 96 (63)
Scalp 29 (19)
Other 20 (13)
Unknown 8 (5)
Questionnaire
First interview (test) 153 (100)
Interview after 2 weeks (retest) 146 (95)
Values are n (%) unless otherwise indicated. AK, actinic kera-
tosis.
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ization was the face. Most participants (95%) were re-in-
terviewed after 2 weeks (Table 1).
Feasibility
There were no missing data: all of the patients respond-
ed to all items. Floor effects ≥85% were found in items 2, 
3 (single-item subscale “global”), 5, 6, and 8. No floor ef-
fects were found in the other subscales or in the total scale.
Reliability
The item responses of the first assessment of the do-
mains of the AKQoL-NL showed a poor internal consis-
tency (Cronbach α = 0.235, 0.297, and 0.468) (Table 2). 
The correlations between domains were lower than those 
obtained in the original scale of Esmann et al. [8] and in 
the two Spanish validation studies (Table 3).
The test-retest reliability (or “repeatability”), which 
was analyzed twice (2 weeks apart) among the 146 pa-
tients who completed the AKQoL, was excellent for all 
domains (Table 4).
Validity
Construct Validity. The AKQoL correlated poorly with 
both the SS and the PSS of the Skindex-17, which was 
used to test convergent validity (Table 5). The correlation 
with the domains of the GFI (divergent validity) were 
lower.
Discriminative Validity. The mean of the AKQoL to-
tal scores increased significantly with the severity of 
AK. The mean scores of patients with mild AK were 
2.81 (SD = 2.67), 3.31 (SD = 2.63) for patients with 
moderate AK, and 5.28 (SD = 3.35) for patients with 
Domain Cronbach α 95% CI
AKQoL-NL overall (total) 0.643 0.552 to 0.722
Emotion (q2, 4, 6) 0.468 0.303 to 0.599
Function (q1, 8, 9) 0.297 0.080 to 0.470
Control (q5, 7) 0.235 –0.053 to 0.444
Global (q3) not applicable not applicable
 AKQoL-NL, Dutch version of the Actinic Keratosis Quality of Life Questionnaire.
Table 2. Internal consistency
Table 3. Observed Spearman rank correlations between domains
Dutch, 
current study
95% CI Danish, 
original study1
Spanish, 
validation study2
Spanish,
validation study3
Emotion (function) 0.373 0.226 to 0.523 0.530 0.652 0.777
Control (function) 0.396 0.254 to 0.519 0.427 0.533 0.566
Control (emotion) 0.412 0.267 to 0.549 0.622 0.568 0.570
1 Esmann et al. [8]. 2 Longo Imedio et al. [9]. 3 Alarcon et al. [10].
Table 4. Test-retest reliability
Domain Test score Retest score Intraclass 
correlation coefficient1
95% CI p value
Emotion 0.94 (1.10) 0.94 (1.11) 0.997 0.996 to 0.998 <0.001
Function 1.61 (1.52) 1.59 (1.51) 1.000 1.000 to 1.000 –
Control 1.04 (1.08) 1.03 (1.09) 1.000 1.000 to 1.000 –
Global 0.07 (0.34) 0.09 (0.39) 1.000 1.000 to 1.000 –
Test and retest score values are mean (SD). 1 One-way random effects model.
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severe AK (Table 6; p < 0.001) with a significant differ-
ence between the moderate AK and severe AK groups 
in the post hoc testing.
Discussion
In this study, we tested the psychometric properties of 
the AKQoL-NL. Our data suggest that the questionnaire 
is feasible. The results on reliability were inconsistent: the 
internal consistency was poor, but the repeatability was 
excellent and inter-item and inter-scale coefficients were 
lower than reported in the other versions of the AKQoL. 
The construct validity of the AKQoL-NL seems reason-
able, as we observed reasonable correlation with a derma-
tological-specific HRQoL instrument (Skindex-17) and 
poor correlation with frailty in general (GFI). The dis-
criminative validity was high for patients with severe AK 
compared to those with mild or moderate disease se- 
verity. 
Feasibility
The AKQoL was developed in Denmark and to date 
only the translation into Spanish has been validated in 
two studies [9, 10]. Comparable to their results we also 
observed floor effects in items 6 and 8 [10], but we ob-
served floor effects in 3 other items as well. This indicates 
that most patients do not have difficulties due to their 
sun-damaged skin or feelings of guilt regarding their sun-
damaged skin. These items may, however, be valuable for 
distinguishing a smaller subgroup of patients with a more 
severe impact of AK on their HRQoL. 
Table 5. Convergent and divergent validity: multitrait-multimethod correlation matrix using the Spearman correlation coefficient
AKQoL
function emotion control global
Convergent validity: Skindex–17
Symptoms 0.295** 0.339** 0.226** 0.015
95% CI 0.147 to 0.431 0.174 to 0.481 0.076 to 0.377 –0.146 to 0.190
Psychosocial 0.332** 0.376** 0.306** 0.338**
95% CI 0.178 to 0.464 0.236 to 0.497 0.142 to 0.456 0.089 to 0.548
Divergent validity: GFI
Physical 0.007 –0.039 –0.106 –0.011
95% CI –0.147 to 0.160 –0.195 to 0.118 –0.262 to 0.055 –0.186 to 0.168
Cognition 0.084 0.001 –0.005 –0.051
95% CI –0.065 to 0.217 –0.149 to 0.131 –0.156 to 0.158 –0.077 to –0.025
Social 0.170* 0.221** 0.143 0.201*
95% CI 0.019 to 0.322 0.058 to 0.374 –0.038 to 0.303 –0.026 to 0.392
Psychological 0.166* 0.234** 0.209** 0.171*
95% CI 0.011 to 0.301 0.079 to 0.381 0.044 to 0.358 –0.024 to 0.353
AKQoL, Actinic Keratosis Quality of Life Questionnaire. * Correlation is significant at the 0.05 level (2-tailed). ** Correlation is 
significant at the 0.01 level (2-tailed).
Table 6. Discriminative validity
AK severity AKQoL 
total score
p value 
for trend
Post hoc testing
p value
Mild (n = 52) 2.81 (2.67) <0.001 1.000 (vs. moderate) 
Moderate (n = 61) 3.31 (2.63) 0.003 (vs. severe) 
Severe (n = 40) 5.28 (3.35)
AKQoL total score value is mean (SD). Mild: 1–3 AKs; moderate: 4–9 AKs; severe: >10 AKs. AK, actinic keratosis; AKQoL, Actinic 
Keratosis Quality of Life Questionnaire.
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Reliability
As our results indicated poor internal consistency for 
the subscales, we would have liked to compare our results 
to the three other studies. However, the Danish as well as 
both of the Spanish studies only reported an overall Cron-
bach alpha, which ranged from 0.81 to 0.91, which was 
higher than our overall estimate (0.64). Combining mul-
tiple correlated constructs (emotion, function, control, 
global) into one scale (AKQoL overall) leads to a high 
Cronbach alpha by definition [19]. As the correlation be-
tween the domains in our study was lower compared to 
the Danish and the Spanish studies, as a logical result the 
Cronbach alpha of the overall AKQoL was also lower. The 
Cronbach alpha per subscale provides information about 
the correlation between the items of one construct. A 
problem of the Cronbach alpha is that it increases with 
the number of items. The AKQoL has only 1–3 items per 
subscale, which leads to a low Cronbach alpha per sub-
scale. Analysis of the item-rest correlation within the 
scales showed good performance of the items (r > 0.20) 
with the exception of item 8 (r = 0.15). Unfortunately, 
both the Spanish as well as the Danish study did not re-
port a Cronbach alpha per subscale, and therefore we are 
unable to determine if the correlation between the items 
of one domain is lower or comparable to other studies. In 
accordance with both Spanish validation studies the test-
retest correlation was high (> 0.9). 
Validity
In order to establish convergent validity, the AKQoL 
was previously compared to both the Dermatology Life 
Quality Index (DLQI) and the Skindex-29. We compared 
the AKQoL with the Skindex-17 which led to correlation 
coefficients (0.226–0.376) comparable to the Skindex-29 
(0.344) [9]. The correlation with the DLQI was much 
higher (> 0.75) [10].
Our study adds information on divergent validity of 
the AKQoL. All previously performed studies did not 
compare the AKQoL with a generic HRQoL instrument. 
We have compared the AKQoL with the GFI, a general 
measure of frailty, which is an important determinant of 
generic HRQoL. As hypothesized, the GFI correlated very 
poorly with the AKQoL, indicating that the AKQoL spe-
cifically measures AK-related HRQoL impairment and 
does not measure poor well-being in general. 
Our study also adds knowledge on the AKQoL perfor-
mance in different severity groups. Both the Danish and 
the Spanish studies did not provide information on dis-
ease severity, possibly because it is difficult to count AKs 
[13]. Therefore, we assessed categories of AK count. We 
observed that the mean AKQoL scores differed between 
patients with mild or moderate AK and patients with se-
vere AK. Patients with mild AK may have little to no im-
paired HRQoL due to their AK, which may explain the 
proportion of floor effects.
Strengths and Limitations
Strengths of our study include the high response rate 
and the inclusion of a large number of patients both in a 
general hospital as well as in a tertiary referral center. This 
led to a diverse group of patients in whom it was possible 
to assess the performance of the AKQoL by disease sever-
ity. Another strength of our study is that we included the 
GFI in order to assess divergent validity. 
A limitation of this study is that the translation is based 
on the English version of the AKQoL, and not the original 
Danish version. Another limitation is that no informa-
tion was gathered on the patients refusing to participate 
in this study.
Future Directions
As we have shown that the mean AKQoL score is differ-
ent for severe AK patients, future research could assess the 
responsiveness of the AKQoL (i.e., if the AKQoL changes 
with treatment response). This is needed to determine if 
the AKQoL can be used in clinical trials for therapy. 
Since the debate on whether to treat or not to treat AK 
is still ongoing [20], the AKQoL may provide additional 
information for the individual patient to decide whether or 
not to treat. On a group level, on the other hand, it may 
help to identify patient groups eligible for treatment be-
forehand (e.g., elderly men with multiple AKs on the scalp).
Future studies should help to determine if the low in-
ternal consistency of the subscales is due to cultural dif-
ferences or due to the design of the questionnaire. There-
fore, the Cronbach alpha per subscale should be deter-
mined in future studies and, ideally, also that of the 
original Danish study.
Conclusion
Our study added important information on the valid-
ity of the AKQoL, showing that it has discriminative va-
lidity on disease severity and that it measures AK-specif-
ic HRQoL and not frailty in general. The internal consis-
tency of the AKQoL-NL was poor, but the repeatability 
was excellent. The AKQoL-NL is a feasible and valid 
HRQoL instrument, but reliability is moderate and there-
fore the AKQoL-NL could be used as a tool to assess dis-
Vis/Waalboer-Spuij/Snels/HollesteinDermatology6
DOI: 10.1159/000489118
ease-specific HRQoL in clinical and research setting. 
Therefore, interpretation of the domain scores must be 
done with great caution. 
Key Message
The Dutch adaptation of the Actinic Keratosis Quality of Life 
Questionnaire (AKQoL-NL) is a feasible, moderately valid, and 
moderately reliable health-related quality of life questionnaire.
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